Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Nam H. Dang, MD, PhD, Mitchell R Smith, MD, PhD, Fritz Offner, MD, Gregor Verhoef, MD, Peter Johnson, MD, Ama Z S Rohatiner, MD, Jonathan L. Kaufman, MD, Eva Gine, M.D., Bertrand Coiffier, MD, Myron S Czuczman, MD, James Foran, MD, Simon Durrant, MD, Steven Hua, PhD, Erik R. Vandendries, MD, PhD, Luis Fayad, MD

Blood (2009) 114 (22): 584.

https://doi.org/10.1182/blood.V114.22.584.584

Published: 2009

Journal Articles

Patterns of Outcome Following Recurrence in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Long Follow-up From a Single Centre.

Shireen Kassam, Silvia Montoto, MD, Andrew Wilson, Janet Matthews, Kim Last, T. Andrew Lister, Ama Z S Rohatiner, MD

Blood (2009) 114 (22): 2921.

https://doi.org/10.1182/blood.V114.22.2921.2921

Published: 2009

Journal Articles

Active Surveillance Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma.

Marco Gerlinger, MD, Janet Matthews, Andy Davies, T. Andrew Lister, Silvia Montoto, MD, Ama Z S Rohatiner, MD

Blood (2008) 112 (11): 3251.

https://doi.org/10.1182/blood.V112.11.3251.3251

Published: 2008

Journal Articles

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

Monica Else, MA, MSc, Claire E. Dearden, MD, Estella Matutes, MD, Ama Z S Rohatiner, MD, Steve A N Johnson, MD, Nigel T J O’Connor, MD, Andy Haynes, MD, Nnenna Osuji, MD, Daniel Catovsky, MD, DSc(Med)

Blood (2008) 112 (11): 2101.

https://doi.org/10.1182/blood.V112.11.2101.2101

Published: 2008

Journal Articles

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.

Franck Morschhauser, Angelika Bischof-Delaloye, Ama Z S Rohatiner, MD, Gilles Andre Salles, MD, PhD, Jens Kuhlmann, Willem JL Van Putten, John Radford, Pierre Soubeyran, Achiel Van Hoof, Anton Hagenbeek

Blood (2008) 112 (11): 2002.

https://doi.org/10.1182/blood.V112.11.2002.2002

Published: 2008

NARROW

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Patterns of Outcome Following Recurrence in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Long Follow-up From a Single Centre.

Active Surveillance Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma.

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Patterns of Outcome Following Recurrence in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Long Follow-up From a Single Centre.

Active Surveillance Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma.

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only